Recombinant Newcastle disease virus-vectored vaccines against human and animal infectious diseases

Future Microbiology

Volumn 10, Issue 8, 2015, Pages 1307-1323

  Duan, Zhiqiang ^a   Xu, Houqiang ^a   Ji, Xinqin ^a   Zhao, Jiafu ^a  

^a GUIZHOU UNIVERSITY   (China)

Author keywords

Newcastle disease virus; protective immune response; reverse genetics technology; vaccine development; virus vectored vaccine

Indexed keywords

NEWCASTLE DISEASE VACCINE; RECOMBINANT VACCINE; VIRUS VECTOR; VIRUS VACCINE;

DRUG EFFICACY; GENE EXPRESSION; GENE STRUCTURE; HUMAN; NEWCASTLE DISEASE; NEWCASTLE DISEASE VIRUS; NONHUMAN; PRIORITY JOURNAL; REVERSE GENETICS; REVIEW; VIRUS GENOME; ANIMAL; COMMUNICABLE DISEASE CONTROL; GENE VECTOR; GENETIC ENGINEERING; GENETICS; HUMORAL IMMUNITY; IMMUNOLOGY; MUCOSAL IMMUNITY; PROCEDURES;

ANIMALS; COMMUNICABLE DISEASE CONTROL; GENETIC ENGINEERING; GENETIC VECTORS; GENOME, VIRAL; HUMANS; IMMUNITY, HUMORAL; IMMUNITY, MUCOSAL; NEWCASTLE DISEASE VIRUS; REVERSE GENETICS; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 84940669301     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/FMB.15.59     Document Type: Review

References (134)

1. Ada G. Overview of vaccines and vaccination. Mol. Biotechnol. 29(3), 255-272 (2005
2. De Groot AS, Einck L, Moise L et al. Making vaccines 'on demand': a potential solution for emerging pathogens and biodefense? Hum. Vaccin. Immunother. 9(9), 1877-1884 (2013
3. Ngcobo NJ, Cameron NA. The decision making process on new vaccines introduction in South Africa. Vaccine 30(Suppl. 3), C9-C13 (2012
4. Gruters R, Osterhaus A. AIDS vaccine research: consider co-infections. Science 319(5868), 1337 (2008
5. Ulbert S, Magnusson SE. Technologies for the development of West Nile virus vaccines. Future Microbiol. 9(10), 1221-1232 (2014
6. Deen JL, Clemens JD. Issues in the design and implementation of vaccine trials in less developed countries. Nat. Rev. Drug. Discov. 5(11), 932-940 (2006
7. Alemayehu D, Utt E, Knirsch C. Vaccines: a review of immune-based interventions to prevent and treat disease. J. Clin. Pharmacol. 55(Suppl. 3), S93-S102 (2015
8. Hoft DF, Brusic V, Sakala IG. Optimizing vaccine development. Cell. Microbiol. 13(7), 934-942 (2011
9. Lovett-Racke AE. Research highlights: highlights from the latest articles in optimizing vaccine development. Immunotherapy 4(5), 469-471 (2012
10. Gregersen JP. DNA vaccines. Naturwissenschaften 88(12), 504-513 (2001
11. Souza AP, Haut L, Reyes-Sandoval A, Pinto AR. Recombinant viruses as vaccines against viral diseases. Braz. J. Med. Biol. Res. 38(4), 509-522 (2005
12. Tripp RA, Tompkins SM. Virus-vectored influenza virus vaccines. Viruses 6(8), 3055-3079 (2014
13. Schnepp BC, Johnson PR. Vector-mediated antibody gene transfer for infectious diseases. Adv. Exp. Med. Biol. 848, 149-167 (2015
14. Xiao S, Kumar M, Yang X et al. A hostrestricted viral vector for antigen-specific immunization against lyme disease pathogen. Vaccine 29(32), 5294-5303 (2011
15. Ganar K, Das M, Sinha S, Kumar S. Newcastle disease virus: current status and our understanding. Virus Res. 184, 71-81 (2014
16. Nakaya T, Cros J, Park MS et al. Recombinant Newcastle disease virus as a vaccine vector. J. Virol. 75(23), 11868-11873 (2001
17. Bukreyev A, Collins PL. Newcastle disease virus as a vaccine vector for humans. Curr. Opin. Mol. Ther. 10(1), 46-55 (2008
18. Huang Z, Elankumaran S, Panda A, Samal SK. Recombinant Newcastle disease virus as a vaccine vector. Poult Sci. 82(6), 899-906 (2003
19. Schirrmacher V, Fournier P. Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer. Methods Mol. Biol. 542, 565-605 (2009
20. Miller PJ, Decanini EL, Afonso CL. Newcastle disease: evolution of genotypes and the related diagnostic challenges. Infect. Genet. Evol. 10(1), 26-35 (2010
21. Mayo MA. A summary of taxonomic changes recently approved by ICTV. Arch. Virol. 147(8), 1655-1663 (2002
22. Kattenbelt JA, Stevens MP, Gould AR. Sequence variation in the Newcastle disease virus genome. Virus Res. 116(1-2), 168-184 (2006
23. Yusoff K, Tan WS. Newcastle disease virus: macromolecules and opportunities. Avian Pathol. 30(5), 439-455 (2001
24. Hamaguchi M, Yoshida T, Nishikawa K, Naruse H, Nagai Y. Transcriptive complex of Newcastle disease virus. I. Both L and P proteins are required to constitute an active complex. Virology 128(1), 105-117 (1983
25. Hamaguchi M, Nishikawa K, Toyoda T, Yoshida T, Hanaichi T, Nagai Y. Transcriptive complex of Newcastle disease virus. II. Structural and functional assembly associated with the cytoskeletal framework. Virology 147(2), 295-308 (1985
26. Pantua HD, Mcginnes LW, Peeples ME, Morrison TG. Requirements for the assembly and release of Newcastle disease virus-like particles. J. Virol. 80(22), 11062-11073 (2006
27. Duan Z, Hu Z, Zhu J et al. Mutations in the FPIV motif of Newcastle disease virus matrix protein attenuate virus replication and reduce virus budding. Arch. Virol. 159(7), 1813-1819 (2014
28. Smith EC, Popa A, Chang A, Masante C, Dutch RE. Viral entry mechanisms: the increasing diversity of paramyxovirus entry. FEBS J. 276(24), 7217-7227 (2009
29. Kurilla MG, Stone HO, Keene JD. RNA sequence and transcriptional properties of the 3' end of the Newcastle disease virus genome. Virology 145(2), 203-212 (1985
30. Krishnamurthy S, Samal SK. Nucleotide sequences of the trailer, nucleocapsid protein gene and intergenic regions of Newcastle disease virus strain Beaudette C and completion of the entire genome sequence. J. Gen. Virol. 79(10), 2419-2424 (1998
31. Walpita P, Flick R. Reverse genetics of negative-stranded RNA viruses: a global perspective. FEMS Microbiol. Lett. 244(1), 9-18 (2005
32. Neumann G, Whitt MA, Kawaoka Y. A decade after the generation of a negativesense RNA virus from cloned cDNA - what have we learned? J. Gen. Virol. 83(11), 2635-2662 (2002
33. Neumann G, Kawaoka Y. Reverse genetics systems for the generation of segmented negative-sense RNA viruses entirely from cloned cDNA. Curr. Top. Microbiol. Immunol. 283, 43-60 (2004
34. Romer-Oberdorfer A, Mundt E, Mebatsion T, Buchholz UJ, Mettenleiter TC. Generation of recombinant lentogenic Newcastle disease virus from cDNA. J. Gen. Virol. 80(11), 2987-2995 (1999
35. Peeters BP, De Leeuw OS, Koch G, Gielkens AL. Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence. J. Virol. 73(6), 5001-5009 (1999
36. Krishnamurthy S, Huang Z, Samal SK. Recovery of a virulent strain of Newcastle disease virus from cloned cDNA: expression of a foreign gene results in growth retardation and attenuation. Virology 278(1), 168-182 (2000
37. De Leeuw OS, Koch G, Hartog L, Ravenshorst N, Peeters BP. Virulence of Newcastle disease virus is determined by the cleavage site of the fusion protein and by both the stem region and globular head of the haemagglutinin-neuraminidase protein. J. Gen. Virol. 86(Pt 6), 1759-1769 (2005
38. Liu YL, Hu SL, Zhang YM et al. Generation of a velogenic Newcastle disease virus from cDNA and expression of the green fluorescent protein. Arch. Virol. 152(7), 1241-1249 (2007
39. Hu Z, Hu S, Meng C, Wang X, Zhu J, Liu X. Generation of a genotype VII Newcastle disease virus vaccine candidate with high yield in embryonated chicken eggs. Avian Dis. 55(3), 391-397 (2011
40. Schnell MJ, Mebatsion T, Conzelmann KK. Infectious rabies viruses from cloned cDNA. EMBO J. 13(18), 4195-4203 (1994
41. Fuerst TR, Niles EG, Studier FW, Moss B. Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. Proc. Natl Acad. Sci. USA 83(21), 8122-8126 (1986
42. Buchholz UJ, Finke S, Conzelmann KK. Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter. J. Virol. 73(1), 251-259 (1999
43. Li BY, Li XR, Lan X et al. Rescue of Newcastle disease virus from cloned cDNA using an RNA polymerase II promoter. Arch. Virol. 156(6), 979-986 (2011
44. Zhang X, Liu H, Liu P, Peeters BP, Zhao C, Kong X. Recovery of avirulent, thermostable Newcastle disease virus strain NDV4-C from cloned cDNA and stable expression of an inserted foreign gene. Arch. Virol. 158(10), 2115-2120 (2013
45. Wang J, Wang C, Feng N et al. Development of a reverse genetics system based on RNA polymerase II for Newcastle disease virus genotype VII. Virus Genes 50(1), 152-155 (2015
46. Le Mercier P, Jacob Y, Tanner K, Tordo N. A novel expression cassette of lyssavirus shows that the distantly related mokola virus can rescue a defective rabies virus genome. J. Virol. 76(4), 2024-2027 (2002
47. Inoue K, Shoji Y, Kurane I, Iijima T, Sakai T, Morimoto K. An improved method for recovering rabies virus from cloned cDNA. J. Virol. Methods 107(2), 229-236 (2003
48. Miller PJ, King DJ, Afonso CL, Suarez DL. Antigenic differences among Newcastle disease virus strains of different genotypes used in vaccine formulation affect viral shedding after a virulent challenge. Vaccine 25(41), 7238-7246 (2007
49. Hu S, Ma H, Wu Y et al. A vaccine candidate of attenuated genotype VII Newcastle disease virus generated by reverse genetics. Vaccine 27(6), 904-910 (2009
50. Xiao S, Nayak B, Samuel A et al. Generation by reverse genetics of an effective, stable, live-Attenuated Newcastle disease virus vaccine based on a currently circulating, highly virulent indonesian strain. PLoS ONE 7(12), e52751 (2012
51. Liu MM, Cheng JL, Yu XH, Qin ZM, Tian FL, Zhang GZ. Generation by reverse genetics of an effective attenuated Newcastle disease virus vaccine based on a prevalent highly virulent Chinese strain. Biotechnol. Lett. 37 (6), 1287-1296 (2015
52. Wang J, Cong Y, Yin R et al. Generation and evaluation of a recombinant genotype VII Newcastle disease virus expressing VP3 protein of goose parvovirus as a bivalent vaccine in goslings. Virus Res. 203, 77-83 (2015
53. Peeters BP, De Leeuw OS, Verstegen I, Koch G, Gielkens AL. Generation of a recombinant chimeric Newcastle disease virus vaccine that allows serological differentiation between vaccinated and infected animals. Vaccine 19(13-14), 1616-1627 (2001
54. Vigil A, Park MS, Martinez O et al. Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Cancer Res. 67(17), 8285-8292 (2007
55. Kim SH, Paldurai A, Xiao S, Collins PL, Samal SK. Modified Newcastle disease virus vectors expressing the H5 hemagglutinin induce enhanced protection against highly pathogenic H5N1 avian influenza virus in chickens. Vaccine 32(35), 4428-4435 (2014
56. Kim SH, Subbiah M, Samuel AS, Collins PL, Samal SK. Roles of the fusion and hemagglutinin-neuraminidase proteins in replication, tropism, and pathogenicity of avian paramyxoviruses. J. Virol. 85(17), 8582-8596 (2011
57. Nayak B, Dias FM, Kumar S, Paldurai A, Collins PL, Samal SK. Avian paramyxovirus serotypes 2-9 (APMV-2-9) vary in the ability to induce protective immunity in chickens against challenge with virulent Newcastle disease virus (APMV-1). Vaccine 30(12), 2220-2227 (2012
58. Samuel AS, Subbiah M, Shive H, Collins PL, Samal SK. Experimental infection of hamsters with avian paramyxovirus serotypes 1 to 9. Vet. Res. 42, 38 (2011
59. Grund C, Steglich C, Huthmann E, Beer M, Mettenleiter TC, Romer-Oberdorfer A. Avian paramyoxvirus-8 immunization reduces viral shedding after homologous APMV-8 challenge but fails to protect against Newcastle disease. Virol. J. 11, 179 (2014
60. Steglich C, Grund C, Ramp K et al. Chimeric Newcastle disease virus protects chickens against avian influenza in the presence of maternally derived NDV immunity. PLoS ONE 8(9), e72530 (2013
61. Nagai Y. Paramyxovirus replication and pathogenesis. Reverse genetics transforms understanding. Rev. Med. Virol. 9(2), 83-99 (1999
62. Zhao H, Peeters BP. Recombinant Newcastle disease virus as a viral vector: effect of genomic location of foreign gene on gene expression and virus replication. J. Gen. Virol. 84(4), 781-788 (2003
63. Bukreyev A, Huang Z, Yang L et al. Recombinant Newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates. J. Virol. 79(21), 13275-13284 (2005
64. Huang Z, Krishnamurthy S, Panda A, Samal SK. High-level expression of a foreign gene from the most 3'-proximal locus of a recombinant Newcastle disease virus. J. Gen. Virol. 82(Pt 7), 1729-1736 (2001
65. He B, Paterson RG, Ward CD, Lamb RA. Recovery of infectious SV5 from cloned DNA and expression of a foreign gene. Virology 237(2), 249-260 (1997
66. Yan Y, Samal SK. Role of intergenic sequences in Newcastle disease virus RNA transcription and pathogenesis. J. Virol. 82(3), 1323-1331 (2008
67. Zhao W, Zhang Z, Zsak L, Yu Q. P and M gene junction is the optimal insertion site in Newcastle disease virus vaccine vector for foreign gene expression. J. Gen. Virol. 96(1), 40-45 (2015
68. Wen G, Chen C, Guo J et al. Development of a novel thermostable Newcastle disease virus vaccine vector for expression of a heterologous gene. J. Gen. Virol. 96, 1219-1228 (2015
69. Susta L, Cornax I, Diel DG et al. Expression of interferon gamma by a highly virulent strain of Newcastle disease virus decreases its pathogenicity in chickens. Microb. Pathog. 61-62, 73-83 (2013
70. Zhao L, Mei Y, Sun Q et al. Autologous tumor vaccine modified with recombinant Newcastle disease virus expressing IL-7 promotes antitumor immune response. J. Immunol. 193(2), 735-745 (2014
71. Bukreyev A, Skiadopoulos MH, Murphy BR, Collins PL. Nonsegmented negative-strand viruses as vaccine vectors. J. Virol. 80(21), 10293-10306 (2006
72. Chare ER, Gould EA, Holmes EC. Phylogenetic analysis reveals a low rate of homologous recombination in negative-sense RNA viruses. J. Gen. Virol. 84(Pt 10), 2691-2703 (2003
73. Song Q, Cao Y, Li Q et al. Artificial recombination may influence the evolutionary analysis of Newcastle disease virus. J. Virol. 85(19), 10409-10414 (2011
74. Shrivastava SR, Shrivastava PS, Ramasamy J. Emerging and re-emerging infectious diseases: public health perspective. Int. J. Prev. Med. 4(6), 736-737 (2013
75. Stramer SL. Current perspectives in transfusion-Transmitted infectious diseases: emerging and re-emerging infections. ISBT Sci. Ser. 9(1), 30-36 (2014
76. Sato H, Yoneda M, Honda T, Kai C. Recombinant vaccines against the mononegaviruses-what we have learned from animal disease controls. Virus Res. 162(1-2), 63-71 (2011
77. Cassel WA, Garrett RE. Newcastle disease virus as an antineoplastic agent. Cancer 18, 863-868 (1965
78. Stojdl DF, Lichty B, Knowles S et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat. Med. 6(7), 821-825 (2000
79. Schirrmacher V, Griesbach A, Ahlert T. Antitumor effects of Newcastle disease virus in vivo: local versus systemic effects. Int. J. Oncol. 18(5), 945-952 (2001
80. Schulze T, Kemmner W, Weitz J, Wernecke KD, Schirrmacher V, Schlag PM. Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial. Cancer Immunol. Immunother. 58(1), 61-69 (2009
81. Lam HY, Yeap SK, Rasoli M et al. Safety and clinical usage of Newcastle disease virus in cancer therapy. J. Biomed. Biotechnol. 2011, 718710 (2011
82. Shobana R, Samal SK, Elankumaran S. Prostate-specific antigen-retargeted recombinant Newcastle disease virus for prostate cancer virotherapy. J. Virol. 87(7), 3792-3800 (2013
83. Sun Y, Zhang Y, Shi C et al. Newcastle disease virus vaccine encapsulated in biodegradable nanoparticles for mucosal delivery of a human vaccine. Hum. Vaccin. Immunother. 10(8), 2503-2506 (2014
84. Jafa K, Mcelroy P, Fitzpatrick L et al. HIV transmission in a state prison system, 1988-2005. PLoS ONE 4(5), e5416 (2009
85. Nickle DC, Jensen MA, Gottlieb GS et al. Consensus and ancestral state HIV vaccines. Science 299(5612), 1515-1518 (2003
86. Nakaya Y, Zheng H, Garcia-Sastre A. Enhanced cellular immune responses to SIV Gag by immunization with influenza and vaccinia virus recombinants. Vaccine 21(17-18), 2097-2106 (2003
87. Piantadosi A, Chohan B, Panteleeff D et al. HIV-1 evolution in gag and env is highly correlated but exhibits different relationships with viral load and the immune response. AIDS 23(5), 579-587 (2009
88. Nakaya Y, Nakaya T, Park MS et al. Induction of cellular immune responses to simian immunodeficiency virus gag by two recombinant negative-strand RNA virus vectors. J. Virol. 78(17), 9366-9375 (2004
89. Carnero E, Li W, Borderia AV, Moltedo B, Moran T, Garcia-Sastre A. Optimization of human immunodeficiency virus Gag expression by Newcastle disease virus vectors for the induction of potent immune responses. J. Virol. 83(2), 584-597 (2009
90. Khattar SK, Samal S, Devico AL, Collins PL, Samal SK. Newcastle disease virus expressing human immunodeficiency virus type 1 envelope glycoprotein induces strong mucosal and serum antibody responses in guinea pigs. J. Virol. 85(20), 10529-10541 (2011).
91. Khattar SK, Samal S, Labranche CC, Montefiori DC, Collins PL, Samal SK. Comparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated Newcastle disease virus vector. PLoS ONE 8(10), e78521 (2013
92. Khattar SK, Palaniyandi SK, Samal S et al. Evaluation of humoral, mucosal and cellular immune responses following coimmunization of HIV-1 Gag and Env proteins expressed by Newcastle disease virus. Hum. Vaccin. Immunother. 11(2), 504-515 (2015
93. Dinapoli JM, Kotelkin A, Yang L et al. Newcastle disease virus, a host rangerestricted virus, as a vaccine vector for intranasal immunization against emerging pathogens. Proc. Natl Acad. Sci. USA 104(23), 9788-9793 (2007
94. Gimm G, Nichols LM. Ebola crisis of 2014: are current strategies enough to meet the long-run challenges ahead? Am. J. Public Health 10 (5) e8-e10 (2015
95. Dinapoli JM, Yang L, Samal SK, Murphy BR, Collins PL, Bukreyev A. Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response. Vaccine 29(1), 17-25 (2010
96. Sivasamugham LA, Cardosa MJ, Tan WS, Yusoff K. Recombinant Newcastle disease virus capsids displaying enterovirus 71 VP1 fragment induce a strong immune response in rabbits. J. Med. Virol. 78(8), 1096-1104 (2006
97. Martinez-Sobrido L, Gitiban N, Fernandez-Sesma A et al. Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector. J. Virol. 80(3), 1130-1139 (2006
98. Kong D, Wen Z, Su H et al. Newcastle disease virus-vectored nipah encephalitis vaccines induce B and T cell responses in mice and long-lasting neutralizing antibodies in pigs. Virology 432(2), 327-335 (2012
99. Kortekaas J, De Boer SM, Kant J, Vloet RP, Antonis AF, Moormann RJ. Rift valley fever virus immunity provided by a paramyxovirus vaccine vector. Vaccine 28(27), 4394-4401 (2010
100. Kim SH, Chen S, Jiang X, Green KY, Samal SK. Newcastle disease virus vector producing human norovirus-like particles induces serum, cellular, and mucosal immune responses in mice. J. Virol. 88(17), 9718-9727 (2014
101. Gebreyes WA, Dupouy-Camet J, Newport MJ et al. The global one health paradigm: challenges and opportunities for tackling infectious diseases at the human, animal, and environment interface in low-resource settings. PLoS Negl. Trop. Dis. 8(11), e3257 (2014
102. England JJ. Animal health emergency diseases. Introduction. Vet. Clin. North Am. Food. Anim. Pract. 18(3), xi-xii (2002
103. Schmaljohn C, Mandl CW. The interface of animal and human vaccines. Curr. Opin. Virol. 2(3), 306-308 (2012
104. Blaxland JD. Vaccines in the prevention and control of avian virus diseases. Veterinarian 3, 79-86 (1965
105. Swayne DE. Vaccines for list a poultry diseases: emphasis on avian influenza. Dev. Biol. (Basel) 114, 201-212 (2003
106. Roche SE, Cogger N, Garner MG, Putra AA, Toribio JA. Assessing the risk of highly pathogenic avian influenza H5N1 transmission through poultry movements in Bali, Indonesia. Prev. Vet. Med. 113(4), 599-607 (2014
107. Hoper D, Kalthoff D, Hoffmann B, Beer M. Highly pathogenic avian influenza virus subtype H5N1 escaping neutralization: more than HA variation. J. Virol. 86(3), 1394-1404 (2012
108. Spackman E, Swayne DE, Pantin-Jackwood MJ et al. Variation in protection of four divergent avian influenza virus vaccine seed strains against eight clade 2.2.1 and 2.2.1.1. Egyptian H5N1 high pathogenicity variants in poultry. Influenza Other Respir. Viruses 8(6), 654-662 (2014
109. Pappaioanou M. Highly pathogenic H5N1 avian influenza virus: cause of the next pandemic? Comp. Immunol. Microbiol. Infect. Dis. 32(4), 287-300 (2009
110. Veits J, Wiesner D, Fuchs W et al. Newcastle disease virus expressing H5 hemagglutinin gene protects chickens against Newcastle disease and avian influenza. Proc. Natl Acad. Sci. USA 103(21), 8197-8202 (2006
111. Ge J, Deng G, Wen Z et al. Newcastle disease virus-based live attenuated vaccine completely protects chickens and mice from lethal challenge of homologous and heterologous H5N1 avian influenza viruses. J. Virol. 81(1), 150-158 (2007
112. Dinapoli JM, Yang L, Suguitan A Jr et al. Immunization of primates with a Newcastle disease virus-vectored vaccine via the respiratory tract induces a high titer of serum neutralizing antibodies against highly pathogenic avian influenza virus. J. Virol. 81(21), 11560-11568 (2007
113. Romer-Oberdorfer A, Veits J, Helferich D, Mettenleiter TC. Level of protection of chickens against highly pathogenic H5 avian influenza virus with Newcastle disease virus based live attenuated vector vaccine depends on homology of H5 sequence between vaccine and challenge virus. Vaccine 26(19), 2307-2313 (2008
114. Dinapoli JM, Nayak B, Yang L et al. Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys. J. Virol. 84(3), 1489-1503 (2010
115. Ferreira HL, Pirlot JF, Reynard F, Van Den Berg T, Bublot M, Lambrecht B. Immune responses and protection against H5N1 highly pathogenic avian influenza virus induced by the Newcastle disease virus H5 vaccine in ducks. Avian Dis. 56(4), 940-948 (2012
116. Swayne DE, Suarez DL, Schultz-Cherry S et al. Recombinant paramyxovirus type 1-Avian influenza-H7 virus as a vaccine for protection of chickens against influenza and Newcastle disease. Avian Dis. 47(3), 1047-1050 (2003
117. Schroer D, Veits J, Grund C et al. Vaccination with Newcastle disease virus vectored vaccine protects chickens against highly pathogenic H7 avian influenza virus. Avian Dis. 53(2), 190-197 (2009
118. Smith J, Sadeyen JR, Butter C, Kaiser P, Burt DW. Analysis of the early immune response to infection by infectious bursal disease virus in chickens differing in their resistance to the disease. J. Virol. 89(5), 2469-2482 (2015
119. Gao L, Qi X, Li K et al. Development of a tailored vaccine against challenge with very virulent infectious bursal disease virus of chickens using reverse genetics. Vaccine 29(33), 5550-5557 (2011
120. Huang Z, Elankumaran S, Yunus AS, Samal SK. A recombinant Newcastle disease virus (NDV) expressing VP2 protein of infectious bursal disease virus (IBDV) protects against NDV and IBDV. J. Virol. 78(18), 10054-10063 (2004
121. Kanabagatte Basavarajappa M, Kumar S, Khattar SK, Gebreluul GT, Paldurai A, Samal SK. A recombinant Newcastle disease virus (NDV) expressing infectious laryngotracheitis virus (ILTV) surface glycoprotein d protects against highly virulent ILTV and NDV challenges in chickens. Vaccine 32(28), 3555-3563 (2014
122. Zhao W, Spatz S, Zhang Z et al. Newcastle disease virus (NDV) recombinants expressing infectious laryngotracheitis virus (ILTV) glycoproteins gB and gD protect chickens against ILTV and NDV challenges. J. Virol. 88(15), 8397-8406 (2014
123. Khattar SK, Collins PL, Samal SK Immunization of cattle with recombinant Newcastle disease virus expressing bovine herpesvirus-1 (BHV-1) glycoprotein D induces mucosal and serum antibody responses and provides partial protection against BHV-1. Vaccine 28(18), 3159-3170 (2010
124. Ge J, Wang X, Tao L et al. Newcastle disease virus-vectored rabies vaccine is safe, highly immunogenic, and provides long-lasting protection in dogs and cats. J. Virol. 85(16), 8241-8252 (2011
125. Chen H, Bu Z. Development and application of avian influenza vaccines in China. Curr. Top. Microbiol. Immunol. 333, 153-162 (2009
126. Kortekaas J, Dekker A, De Boer SM et al. Intramuscular inoculation of calves with an experimental Newcastle disease virus-based vector vaccine elicits neutralizing antibodies against Rift Valley fever virus. Vaccine 28(11), 2271-2276 (2010
127. Dinapoli JM, Ward JM, Cheng L et al. Delivery to the lower respiratory tract is required for effective immunization with Newcastle disease virus-vectored vaccines intended for humans. Vaccine 27(10), 1530-1539 (2009
128. Mathew A, Townsley E, Ennis FA. Elucidating the role of T cells in protection against and pathogenesis of dengue virus infections. Future Microbiol. 9(3), 411-425 (2014
129. Centlivre M, Combadiere B. New challenges in modern vaccinology. BMC Immunol. 16, 18 (2015
130. Zhao K, Chen G, Shi XM et al. Preparation and efficacy of a live Newcastle disease virus vaccine encapsulated in chitosan nanoparticles. PLoS ONE 7(12), e53314 (2012
131. Zhao K, Li W, Huang T et al. Preparation and efficacy of Newcastle disease virus DNA vaccine encapsulated in PLGA nanoparticles. PLoS ONE 8(12), e82648 (2013
132. Sun Y, Zhang Y, Shi C et al. Newcastle disease virus vaccine encapsulated in biodegradable nanoparticles for mucosal delivery of a human vaccine. Hum. Vaccin. Immunother. 10(8), 2503-2506 (2014
133. Zhao K, Zhang Y, Zhang X et al. Preparation and efficacy of Newcastle disease virus DNA vaccine encapsulated in chitosan nanoparticles. Int. J. Nanomedicine 9, 389-402 (2014
134. Lawrence TM, Wanjalla CN, Gomme EA et al. Comparison of heterologous primeboost strategies against human immunodeficiency virus type 1 Gag using negative-stranded RNA viruses. PLoS ONE 8(6), e67123 (2013